The AIRR Community Diagnostics Working was formed to explore the possibility of applying AIRR-seq technology as a diagnostic tool to the clinics. Our goals include: evaluate the usage of AIRR-seq data for diagnostic purposes, identify bottlenecks or challenges for AIRR-seq based clinical assays, collaborate with other AIRR Community working groups to brainstorm and promote further development and applications of AIRR-seq clinical testing, represent a link between the AIRR-seq community and regulatory agencies when it comes to the potential use of AIRR-seq as a diagnostic tool, and support the AIRR Community efforts with regard to the sequencing analysis of the immune response against the novel coronavirus SARS-CoV-2.
The questions, answers and comments posted under this Expert Q&A forum reflect the views of the author(s) and should not be construed to represent views or policies held by the FDA. Experts answer questions at their discretion and thus not all questions may be addressed. The Expert Q&A forum is also not intended to address questions pertaining to medical advice, diagnosis or treatment.